June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
The clinical efficacy of higher molecular weight sodium hyaluronate in artificial tears: A randomised clinical trial
Author Affiliations & Notes
  • David Semp
    Aston University, Birmingham, Birmingham, United Kingdom
  • Debarun Dutta
    Aston University, Birmingham, Birmingham, United Kingdom
  • James S.W Wolffsohn
    Aston University, Birmingham, Birmingham, United Kingdom
  • Footnotes
    Commercial Relationships   David Semp None; Debarun Dutta Novoxel, Code C (Consultant/Contractor), Johnson and Johnson, Bausch and Lomb, Code F (Financial Support); James Wolffsohn AOS, Medmont, Santen, CSIDryEye, Bausch & Lomb, Alcon, CooperVision, M2C Pharmaceuticals, Novartis, NuVision, Scope Ophthalmics, Théa, Code C (Consultant/Contractor), Johnson & Johnson Vision, Rayner, Topcon, The Eye Doctor, Allergan, Alcon, CooperVision, M2C Pharmaceuticals, Novartis, NuVision, Scope Ophthalmics, Théa, Code F (Financial Support), Aston Vision Sciences, Wolffsohn Research Limited, Eyoto, Code S (non-remunerative)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3970. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David Semp, Debarun Dutta, James S.W Wolffsohn; The clinical efficacy of higher molecular weight sodium hyaluronate in artificial tears: A randomised clinical trial. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3970.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To ascertain whether the molecular weight of sodium hyaluronate in artificial tears, affects its clinical efficacy

Methods : The rheology of HydraMed, Evolve and Hylo-Forte eye drops, which all contain 0.2% hyaluronic acid as the principal component, was assessed using a research rheometer fitted with a 60mm aluminium flat plate measuring system at 31°C. Shear rate profiling was performed on each artificial tear. A total of 25 participants diagnosed with dry eye disease (TFOS DEWS II criteria), aged 23.6±9.2 years, were randomly allocated to receive each drop, on different days. Comfort, non-invasive breakup time, tear meniscus height and ocular redness was assessed at baseline and then 5, 15, 30, 45, 60 and 90 minutes after application.

Results : Hylo-Forte showed a more non-Newtonian relationship between viscosity and sheer force (r2=0.295) compared to HydraMed (r2=0.485) and Evolve (r2=0.521). Comfort and tear stability improved with drop instillation (p>0.05), declining with time (p<0.001), with all drops following a similar profile (p>0.05). Hylo-Forte demonstrated the highest comfort and tear stability retention effect. Tear volume increased with drop instillation and then declined with time (F=18.643, p<0.001). Evolve had a reduced initial effect compared to HydraMed and Hylo-Forte (F=4.045, p<0.001). Average bulbar redness was low (0.63±0.44 Efron grade) and did not change with drop application (F=1.721, p=0.120).

Conclusions : The molecular weight and rheology of sodium hyaluronate in artificial tears leads to differences in clinical effectiveness. The intra-blink viscosity reduces (which may reduce frictional effects) compared to the inter-blink viscosity, increasing in-eye retention and comfort.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×